Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDJLY9)

• Drug Name: NM-702 Drug Info
• Synonyms: NM-702; Parogrelil hydrochloride; UNII-65O9DMS368; 65O9DMS368; NM702; NM 702; 878796-94-2; SCHEMBL1739368; QWGUGDYWUADMGB-UHFFFAOYSA-N; 3(2H)-Pyridazinone, 4-bromo-6-(3-(4-chlorophenyl)propoxy)-5-((3-pyridinylmethyl)amino)-, hydrochloride (1:1); 139145-84-9; 4-bromo-6-(3-(4-chlorophenyl)propoxy)-5-(3-pyridylmethylamino)-3(2H)-pyridazinone hydrochloride

Indication

Disease Entry	ICD 11	Status	REF
Angina pectoris	BA40	Phase 3	[1]

• Cross-matching ID:
  PubChem CID: 9848253
  CAS Number: CAS 878796-94-2
  TTD Drug ID: DMDJLY9

Molecule-Related Drug Atlas

Drug(s) Targeting Thromboxane-A synthase (TBXAS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PYRIDINE	DMF8CJ9	N. A.	N. A.	Phase 4	[3]
E-6700	DMUWJI4	Asthma	CA23	Phase 2	[4]
FK-070	DMJSD5W	Angina pectoris	BA40	Phase 2	[5]
EV-077	DM1FCDH	Type-2 diabetes	5A11	Phase 2	[6]
G-619	DM3H6YC	Thrombosis	DB61-GB90	Phase 1	[7]
NV-52	DM0UOA9	Inflammatory bowel disease	DD72	Phase 1	[8]
Satigrel	DM4LSJ2	Thrombosis	DB61-GB90	Discontinued in Preregistration	[9]
MILACAINIDE TARTRATE	DMJLNUD	Cardiac arrhythmias	BC9Z	Discontinued in Phase 2	[10]
Imitrodast	DMQ2ULV	Asthma	CA23	Discontinued in Phase 2	[11]
Rolafagrel	DM8Q7XV	Nephritis	GB40	Discontinued in Phase 2	[12]

Drug(s) Targeting Phosphodiesterase (PDE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
M-518101	DMZ6VD5	Plaque psoriasis	EA90.0	Phase 3	[13]
Piroximone	DMQXJDM	Cardiac failure	BD10-BD13	Discontinued in Phase 3	[14]
AA-2379	DM78623	Inflammation	1A00-CA43.1	Discontinued in Phase 2	[15]
HN-10200	DMYJ1ZB	Cardiac failure	BD10-BD13	Discontinued in Phase 2	[16]
TIBENELAST	DMYH2PU	Asthma	CA23	Discontinued in Phase 2	[17]
ALBIFYLLINE	DMVBKLO	Sepsis	1G40-1G41	Discontinued in Phase 1	[18]
Sch-45752	DME9Q3V	Asthma	CA23	Terminated	[19]
Isomazole	DM4YJ2W	Asthma	CA23	Terminated	[20]
BBB-022	DMITV4F	Cerebrovascular ischaemia	8B1Z	Terminated	[21]
JTT-608	DMZBNHC	Diabetic complication	5A2Y	Terminated	[22]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphodiesterase (PDE)	TTUST1O	NOUNIPROTAC	Inhibitor	[2]
Thromboxane-A synthase (TBXAS1)	TTKNWZ4	THAS_HUMAN	Inhibitor	[2]

References

• [1] Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. Trials. 2011; 12: 134.
• [2] The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol. 2006 Dec 19;48(12):2539-45.
• [3] Highly selective inhibitors of thromboxane synthetase. 2. Pyridine derivatives. J Med Chem. 1981 Oct;24(10):1149-55.
• [4] Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase. J Med Chem. 1996 Aug 2;39(16):3148-57.
• [5] Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers. J Pharm Pharmacol. 1996 Apr;48(4):380-5.
• [6] Company report (Pharmaceuticalintelligence)
• [7] G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, inhibits tumor necrosis factor-alpha biosynthesis. Eur J Pharmacol. 1995 Nov 3;286(1):31-9.
• [8] Phase Ib single- and multiple-dose pharmacokinetic study of oral NV-52 in healthy volunteers. Drugs R D. 2008;9(3):159-66.
• [9] Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities. Biol Pharm Bull. 1996 Jun;19(6):828-33.
• [10] Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory activity. J Pharmacol Exp Ther. 1996 Nov;279(2):877-83.
• [11] RS-5186, a novel thromboxane synthetase inhibitor with a potent and extended duration of action. Thromb Res. 1988 Sep 1;51(5):507-20.
• [12] Inhibition by FCE 22178 of platelet and glomerular thromboxane synthase in animal and human kidney disease. Adv Prostaglandin Thromboxane Leukot Res. 1991;21B:707-10.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Circulatory effects of the PDE-inhibitors piroximone and enoximone. Br J Clin Pharmacol. 1993 Oct;36(4):309-14.
• [15] Inhibitory effects of methyl 7-butyl-4,5,6,7-tetrahydro-3-methylamino-4,6-dioxo-5-propyl- 2H-pyrazolo[3,4-d]pyrimidine-2-carboxylate (AA-2379) on lysosomal enzyme and arachidonic acid release from rat polymorphonuclear leukocytes and its mode of action. Agents Actions. 1989 Nov;28(3-4):248-55.
• [16] HN-10200 causes endothelium-independent relaxations in isolated canine arteries. Cardiovasc Drugs Ther. 1992 Apr;6(2):159-65.
• [17] Effect of tibenelast (a phosphodiesterase inhibitor) and theophylline on isoproterenol-stimulated heart rate, cyclic AMP and norepinephrine levels. Pharmacology. 1993;46(3):142-7.
• [18] Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur J Immunol. 1995 Jan;25(1):147-53.
• [19] SCH 45752--an inhibitor of calmodulin-sensitive cyclic nucleotide phosphodiesterase activity. J Antibiot (Tokyo). 1993 Feb;46(2):207-13.
• [20] Effects of isomazole on force of contraction and phosphodiesterase isoenzymes I-IV in nonfailing and failing human hearts. J Cardiovasc Pharmacol. 1991 Sep;18(3):386-97.
• [21] Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J Cereb Blood Flow Metab. 2001 Dec;21(12):1393-400.
• [22] JTT-608 controls blood glucose by enhancement of glucose-stimulated insulin secretion in normal and diabetes mellitus rats. Eur J Pharmacol. 1999 Feb 12;367(1):91-9.